Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cambrex Corp (CBM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,742,495
  • Shares Outstanding, K 32,570
  • Annual Sales, $ 490,640 K
  • Annual Income, $ 81,680 K
  • 36-Month Beta 2.09
  • Price/Sales 3.56
  • Price/Cash Flow 15.10
  • Price/Book 4.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.35 +4.58%
on 05/15/17
62.95 -14.69%
on 05/04/17
-5.10 (-8.67%)
since 04/26/17
3-Month
49.40 +8.70%
on 03/15/17
62.95 -14.69%
on 05/04/17
-2.20 (-3.94%)
since 02/24/17
52-Week
38.30 +40.21%
on 11/03/16
62.95 -14.69%
on 05/04/17
+4.92 (+10.09%)
since 05/26/16

Most Recent Stories

More News
Cambrex Reports First Quarter 2017 Financial Results

- Net Revenue increased 11% and EBITDA increased 26% vs. prior year quarter -

CBM : 53.65 (+0.28%)
Cambrex to Announce First Quarter 2017 Financial Results on May 4, 2017

Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2017 financial results will be...

CBM : 53.65 (+0.28%)
SmarTrend Watching for Potential Pullback in Shares of Cambrex After 4.38% Gain

Cambrex (NYSE:CBM) traded in a range yesterday that spanned from a low of $53.00 to a high of $55.60. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of $53.35 on...

CBM : 53.65 (+0.28%)
Does Cambrex Offer a Great Value Buying Opportunity Right Now?

Value investing is easily one of the most popular ways to find great stocks in any market environment.

CBM : 53.65 (+0.28%)
Cambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017

Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that fourth quarter and full year 2016 financial...

CBM : 53.65 (+0.28%)
Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

RHHBY : 34.0650 (-0.89%)
VNDA : 14.27 (+1.57%)
CBM : 53.65 (+0.28%)
Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

RHHBY : 34.0650 (-0.89%)
VNDA : 14.27 (+1.57%)
CBM : 53.65 (+0.28%)
Momenta (MNTA) to Receive $50M Under CSL Collaboration

Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.

MYL : 39.82 (-0.03%)
NVS : 80.70 (-0.80%)
MNTA : 14.93 (-0.47%)
CBM : 53.65 (+0.28%)
Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

NVS : 80.70 (-0.80%)
RHHBY : 34.0650 (-0.89%)
REGN : 456.77 (+0.23%)
CBM : 53.65 (+0.28%)
Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

SNC : 17.46 (+2.59%)
BAK : 20.54 (+0.64%)
DQ : 22.58 (-0.75%)
ICAGY : 15.6580 (-1.83%)
CBM : 53.65 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance...

See More

Support & Resistance

2nd Resistance Point 54.27
1st Resistance Point 53.88
Last Price 53.65
1st Support Level 53.13
2nd Support Level 52.77

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.